Shi, C., Ju, H., Zhou, R., Xu, S., Wu, Y., Gu, Z., . . . Ren, G. (2024). The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification. BMC Medicine, 22(1), . https://doi.org/10.1186/s12916-024-03431-x
Chicago-referens (17:e uppl.)Shi, Chaoji, et al. "The Efficacy and Safety of Dalpiciclib, a Cyclin-dependent Kinase 4/6 Inhibitor, in Patients with Advanced Head and Neck Mucosal Melanoma Harboring CDK4 Amplification." BMC Medicine 22, no. 1 (2024). https://doi.org/10.1186/s12916-024-03431-x.
MLA-referens (9:e uppl.)Shi, Chaoji, et al. "The Efficacy and Safety of Dalpiciclib, a Cyclin-dependent Kinase 4/6 Inhibitor, in Patients with Advanced Head and Neck Mucosal Melanoma Harboring CDK4 Amplification." BMC Medicine, vol. 22, no. 1, 2024, https://doi.org/10.1186/s12916-024-03431-x.
